A new collaboration between Insilico Medicine and Eli Lilly and Company (Lilly) aims to accelerate the discovery and development of novel therapeutics using artificial intelligence across multiple disease areas.
Insilico Medicine has announced a global drug discovery and development agreement with Lilly, centred on the use of AI technologies to support research across a range of therapeutic fields.
The collaboration will use Insilico’s AI engine and its Pharma. AI platforms alongside Lilly’s clinical development capabilities and disease-area expertise. The companies will work together on multiple R&D programmes focused on targets selected by Lilly.
As part of the agreement, Lilly receives an exclusive worldwide licence to develop, manufacture and commercialise a portfolio of potentially best-in-class oral therapeutics that are currently in preclinical development for selected indications.
From its inception, Insilico Medicine has been developing deep learning for end-to-end drug discovery. By deploying frontier AI technologies that scale from biomarkers to life models, world models of human and animal life, we can identify multi-purpose targets driving multiple diseases at the same time.
Alex Zhavoronkov, founder and CEO of Insilico Medicine
“Working with Lilly, we aim to deliver transformative therapies that treat diseases with high unmet need. This collaboration is a testament to the power of AI in tackling the most complex challenges in human health.”
Under the terms of the agreement, Insilico will receive an upfront payment of $115 million and may be eligible for additional development, regulatory and commercial milestone payments, bringing the total potential value of the deal to around $2.75 billion. The agreement also includes tiered royalties on future product sales.
“Insilico’s AI-enabled discovery capabilities represent a powerful complement to Lilly’s deep expertise in clinical development across multiple therapeutic areas,” said Andrew Adams, Group Vice President of Molecule Discovery at Lilly.
“This collaboration allows us to explore novel mechanisms and accelerate the identification of promising therapeutic candidates across multiple disease areas.”
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet.
The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
31.03.2026.
